IPI 201(Isosceles Pharmaceuticals Inc )

N/A

Report date: 2022/12/02 17:15:08
NME

Base Information

Drug NameIPI 201(Isosceles Pharmaceuticals Inc )
Drug Alias NameCannabidiol intravenousIPI-201
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB1 receptor agonistsCannabinoid CB2 receptor agonists
TargetsCannabinoid CB1 receptorCannabinoid CB2 receptor
Therapy Area/IndicationsPain, Postoperative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsPain, Postoperative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A